JP2024516230A5 - - Google Patents

Info

Publication number
JP2024516230A5
JP2024516230A5 JP2023566463A JP2023566463A JP2024516230A5 JP 2024516230 A5 JP2024516230 A5 JP 2024516230A5 JP 2023566463 A JP2023566463 A JP 2023566463A JP 2023566463 A JP2023566463 A JP 2023566463A JP 2024516230 A5 JP2024516230 A5 JP 2024516230A5
Authority
JP
Japan
Prior art keywords
patient
copy
nsclc
genome
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023566463A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516230A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/026919 external-priority patent/WO2022232503A1/en
Publication of JP2024516230A publication Critical patent/JP2024516230A/ja
Publication of JP2024516230A5 publication Critical patent/JP2024516230A5/ja
Pending legal-status Critical Current

Links

JP2023566463A 2021-04-30 2022-04-29 がんのための治療及び診断方法並びに組成物 Pending JP2024516230A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163182307P 2021-04-30 2021-04-30
US63/182,307 2021-04-30
US202163226634P 2021-07-28 2021-07-28
US63/226,634 2021-07-28
US202163256873P 2021-10-18 2021-10-18
US63/256,873 2021-10-18
PCT/US2022/026919 WO2022232503A1 (en) 2021-04-30 2022-04-29 Therapeutic and diagnostic methods and compositions for cancer

Publications (2)

Publication Number Publication Date
JP2024516230A JP2024516230A (ja) 2024-04-12
JP2024516230A5 true JP2024516230A5 (enExample) 2025-05-01

Family

ID=81749220

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023566463A Pending JP2024516230A (ja) 2021-04-30 2022-04-29 がんのための治療及び診断方法並びに組成物

Country Status (4)

Country Link
US (1) US20240052430A1 (enExample)
EP (1) EP4330436A1 (enExample)
JP (1) JP2024516230A (enExample)
WO (1) WO2022232503A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119372341B (zh) * 2024-12-30 2025-04-11 北京致谱医学检验实验室有限公司 基于基因甲基化检测实现人nk淋巴细胞计数的试剂盒

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DK1975181T3 (da) 1992-10-28 2011-06-06 Genentech Inc Anvendelse af vaskulære endothelcelle-vækstfaktor-antagonister
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
DE69832970T2 (de) 1997-04-07 2006-08-10 Genentech, Inc., South San Francisco Humanisierte antikörper und verfahren zu ihrer herstellung
IL132240A0 (en) 1997-04-07 2001-03-19 Genentech Inc Anti-vegf antibodies
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
DE19937264A1 (de) 1999-08-06 2001-02-15 Deutsches Krebsforsch F¶v¶-Antikörper-Konstrukte
NZ621449A (en) 2003-05-30 2015-07-31 Genentech Inc Treatment with anti-vegf antibodies
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US20060009360A1 (en) 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
PL2161336T5 (pl) 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
GB0510790D0 (en) 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
CA2612241C (en) 2005-07-01 2018-11-06 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
JP2012500652A (ja) 2008-08-25 2012-01-12 アンプリミューン、インコーポレーテッド 標的化共刺激ポリペプチドおよび癌を処置するための使用方法
EP4209510B1 (en) 2008-12-09 2024-01-31 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
NO2504364T3 (enExample) 2009-11-24 2018-01-06
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
SI2699264T1 (en) 2011-04-20 2018-08-31 Medimmune Llc Antibodies and other molecules that bind b7-h1 and pd-1
US9096642B2 (en) 2011-06-08 2015-08-04 Aurigene Discovery Technologies Limited Therapeutic compounds for immunomodulation
CN104159911A (zh) 2012-03-07 2014-11-19 奥瑞基尼探索技术有限公司 作为免疫调节剂的模拟肽化合物
EP2831108A1 (en) 2012-03-29 2015-02-04 Aurigene Discovery Technologies Limited Immunomodulating cyclic compounds from the bc loop of human pd1
AU2013267161A1 (en) 2012-05-31 2014-11-20 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
JP6742903B2 (ja) 2013-05-02 2020-08-19 アナプティスバイオ インコーポレイティッド プログラム死−１（ｐｄ−１）に対する抗体
US9676853B2 (en) 2013-05-31 2017-06-13 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-1
CN104250302B (zh) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
CN105814028B (zh) 2013-09-06 2018-02-16 奥瑞基尼探索技术有限公司 作为免疫调节剂的1，2，4‑*二唑衍生物
EP3385257A1 (en) 2013-09-06 2018-10-10 Aurigene Discovery Technologies Limited 1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators
ES2683356T3 (es) 2013-09-06 2018-09-26 Aurigene Discovery Technologies Limited Compuestos peptidomiméticos cíclicos como inmunomoduladores
WO2015036927A1 (en) 2013-09-10 2015-03-19 Aurigene Discovery Technologies Limited Immunomodulating peptidomimetic derivatives
LT3702373T (lt) 2013-09-13 2022-11-10 Beigene Switzerland Gmbh Anti-pd1 antikūnai ir jų naudojimas terapijai ir diagnostikai
WO2015044900A1 (en) 2013-09-27 2015-04-02 Aurigene Discovery Technologies Limited Therapeutic immunomodulating compounds
HUE046249T2 (hu) 2013-12-12 2020-02-28 Shanghai hengrui pharmaceutical co ltd PD-1 antitest, antigén-kötõ fragmense, és gyógyászati alkalmazása
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
CA2935423C (en) 2014-01-24 2023-11-07 Dana-Farber Cancer Institute, Inc. Antibody molecules to pd-1 and uses thereof
SI3102605T1 (sl) 2014-02-04 2019-04-30 Pfizer Inc. Kombinacija PD-1 antagonista in VEGFR inhibitorja za zdravljenje raka
ES2783026T3 (es) 2014-02-04 2020-09-16 Pfizer Combinación de un antagonista de PD-1 y un agonista de 4-1BB para el tratamiento de cáncer
TWI726608B (zh) 2014-07-03 2021-05-01 英屬開曼群島商百濟神州有限公司 抗pd-l1抗體及其作為治療及診斷之用途
CA2955676A1 (en) 2014-08-25 2016-03-03 Pfizer Inc. Combination of a pd-1 antagonist and an alk inhibitor for treating cancer
WO2016061142A1 (en) 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof
WO2016089873A1 (en) 2014-12-02 2016-06-09 Celgene Corporation Combination therapies
US20170363614A1 (en) 2014-12-22 2017-12-21 Enumeral Biomedical Holdings, Inc. Methods For Screening Therapeutic Compounds
IL255312B (en) 2015-05-12 2022-08-01 Genentech Inc Therapeutic and diagnostic methods for cancer containing a pd–l1 binding antagonist
HK1248773A1 (zh) 2015-05-29 2018-10-19 豪夫迈‧罗氏有限公司 用於癌症的治疗和诊断方法
CA3009852A1 (en) 2015-12-28 2017-07-06 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
BR112018013074A2 (en) 2015-12-30 2018-12-11 Novartis Ag immune effector cell therapies with enhanced efficacy
EP3774914A2 (en) 2018-04-13 2021-02-17 Affimed GmbH Nk cell engaging antibody fusion constructs
EP3880246A4 (en) * 2018-11-15 2022-08-10 Personal Genome Diagnostics Inc. METHODS TO IMPROVE RESPONSE PREDICTION IN IMMUNOTHERAPY-TREATED CANCER PATIENTS
US20220154295A1 (en) * 2019-03-27 2022-05-19 The Johns Hopkins University Methods and materials for assessing and treating cancer

Similar Documents

Publication Publication Date Title
Villacampa et al. Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer
US20230295302A1 (en) Methods of treating tumor
US11326211B2 (en) Blood-based biomarkers of tumor sensitivity to PD-1 antagonists
JP2019521641A5 (enExample)
AU2018240295A1 (en) Biomarkers and car T cell therapies with enhanced efficacy
US10711312B2 (en) Methods for immunotherapy-based treatment and assessment of cancer
JP2020535119A5 (enExample)
US20180010132A1 (en) Inhibition of prmt5 to treat mtap-deficiency-related diseases
JP2020513788A5 (enExample)
JP2018526323A5 (enExample)
WO2020033700A9 (en) Methods for assessing the risk of developing progressive multifocal leukoencephalopathy caused by john cunningham virus by genetic testing
JP2025131692A (ja) 腫瘍を処置する方法
US20220185886A1 (en) Methods for identifying biomarkers to predict treatment response
JP2024511373A5 (enExample)
JP2024506839A (ja) キナーゼ阻害剤を用いてがんを処置する方法
US20240254235A1 (en) Compositions and methods for treating lung cancer
CN113677402A (zh) 治疗肿瘤的方法
US20230405117A1 (en) Methods and systems for classification and treatment of small cell lung cancer
Iskierka-Jażdżewska et al. Chronic lymphocytic leukemia: what clinical progress have we seen in the last five years?
JP2023520515A5 (enExample)
US20260042840A1 (en) Methods of treating tumor
CN114174537A (zh) 细胞定位特征和组合疗法
WO2020243568A1 (en) Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy
EP4526477A2 (en) Methods and systems for molecular subtyping of cancer metastases
JP2024516230A (ja) がんのための治療及び診断方法並びに組成物